✦ LIBER ✦

75 A pilot study of adjuvant postoperative chemohormonal therapy with 5-fluorouracil, doxorubicin, cyclophosphamide, vindesine and tamoxifen for resectable breast cancer

✍ Scribed by V. Alonso; J. Florian; M. Alonso; R. Cajal; A. Yubero; M.D. Isla; P. Escudero; A. Saenz; J.I. Mayordomo; A. Tres

Book ID: 116166831
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 144 KB
Volume: 31
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(95)95327-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant chemohormonal therapy with cycl

Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An eastern cooperative oncology group trial

✍ Douglass C. Tormey; Robert Gray; Kennedy Gilchrist; Theodore Grage; Paul P. Carb 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 719 KB

Uracil-tegafur and tamoxifen versus cycl

Uracil-tegafur and tamoxifen versus cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in postoperative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study

✍ Park, Y; Okamura, K; Mitsuyama, S; Saito, T; Koh, J; Kyono, S; Higaki, K; Ogita, 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 44 KB

Randomized trial to evaluate the additio

Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer

✍ James N. Ingle; Lloyd K. Everson; H. Sam Wieand; Stephen A. Cullinan; Lester E. 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 787 KB

PCN12 IMPACT OF ADJUVANT CHEMOTHERAPY WI

PCN12 IMPACT OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER: COST-EFFECTIVENESS ANALYSIS (CEA) OF A DOCETAXEL, DOXORUBICIN AND CYCLOPHOSPHAMIDE REGIMEN (TAC) VERSUS 5-FLUOROURACIL, DOXORUBICIN AND CYCLOPHOSPHAMIDE (FAC) IN FRANCE

✍ H Miadi-Fargier; C Le Pen; MC Woronoff-Lemsi; JP Guastalla; X Pivot; H Roché; F 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

A combination therapy with mitomycin c,

A combination therapy with mitomycin c, etoposide, doxifluridine and medroxyprogesterone acetate as second line therapy for advanced breast cancer refractory to combination chemotherapy of cyclophosphamide, doxorubicin and 5 fluorouracil

✍ Katsumasa Kuroi; Akihiko Osaki; Hiroyuki Kawami; Shigeru Murakami; Tetsuya Toge 📂 Article 📅 1997 🏛 Springer Japan 🌐 English ⚖ 374 KB

Adjuvant six cycles of high-dose adriamy

Adjuvant six cycles of high-dose adriamycin, cyclophosphamide, methotrexate, 5-fluorouracil (ACMF) vs. 12 cycles of low-dose acmf with tamoxifen for premenopausal, node-positive breast cancer patients: Results of a prospective randomized study

✍ Dr. Takashi Fukutomi; Sadako Akashi; Takeshi Nanasawa; Hiroshi Yamamoto 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 398 KB

A prospective randomized study was conducted to compare the adjuvant efficacy of six cycles of high-dose ACMF (Adriamycin, ADM; cyclophosphamide, CPA; methotrexate, MTX; 5-fluorouracil, 5-FU) with that of 12 cycles of low-dose ACMF in premenopausal, node-positive breast cancer patients. The six-cycl